BioMarin Pharmaceutical has acquired ZyStor Therapeutics, a privately held US biotechnology company developing enzyme replacement therapies (ERTs) for the treatment of lysosomal storage disorders. ZyStor's lead product candidate, ZC-701 for the treatment of Pompe disease, is slated to enter the clinic next year.
BioMarin Pharmaceutical has acquired ZyStor Therapeutics, a privately held US biotechnology company developing enzyme replacement therapies (ERTs) for the treatment of lysosomal storage disorders. ZyStor's lead product candidate, ZC-701 for the treatment of Pompe disease, is slated to enter the clinic next year.
Under the agreement, BioMarin bought ZyStor for $22 million up front and up to an additional $93 million if certain...
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.
Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?
